Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PALB2 inact mut |
| Therapy | unspecified PARP inhibitor |
| Indication/Tumor Type | prostate cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PALB2 inact mut | prostate cancer | predicted - sensitive | unspecified PARP inhibitor | Clinical Study - Meta-analysis | Actionable | In a combined analysis of 6 clinical trials, PARP inhibitor therapy improved radiographic progression-free survival (14 vs 9 mo, HR 0.52) and overall survival (25 vs 20 mo, HR 0.78) compared to placebo when combined with AR pathway inhibitors in patients with metastatic castration-resistant prostate cancer harboring PALB2 mutations, and resulted in an objective response rate of 14% (1/7) as monotherapy (PMID: 38484203; NCT02987543, NCT03732820, NCT03395197, NCT03748641, NCT02952534, NCT03148795). | 38484203 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38484203) | Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis. | Full reference... |